People living with pulmonary fibrosis know better than anyone the impact this progressive and irreversible lung disease can have on everyday life. Your experience could help inform an important decision about a potential new treatment, nerandomilast (Jascayd®), which is being considered for listing on the Pharmaceutical Benefits Scheme (PBS) for people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) at the November 2026 PBAC meeting.

What is the PBAC?

The Pharmaceutical Benefits Advisory Committee (PBAC) is an independent expert committee that advises the Australian Government on which medicines should be subsidised through the PBS. When making its recommendations, the PBAC considers clinical evidence, economic evidence and, importantly, the experiences of patients, carers and families.

That’s why your voice matters.

How can I share my experience?

There are three ways you can contribute:

1. Share your story using Patient Input Buddy

We know it can be difficult to know what information is most helpful for decision-makers. To make the process easier, an online tool called Patient Input Buddy is available to help you prepare your submission.

Developed by Boehringer Ingelheim in consultation with Scleroderma Australia, Lung Foundation Australia, Patient Voice Initiative and Rare Cancers Australia, Patient Input Buddy guides you through a series of simple prompts. You can type your responses or speak them using voice-to-text. The tool then helps turn your experiences into a clear submission that you can send directly to the PBAC.

Visit www.patientinput.com.au to get started.

2. Submit directly to the PBAC

You can also provide your feedback directly to the PBAC through the Australian Government consultation process. The PBAC welcomes comments from patients, carers, family members and consumer organisations to help it better understand the real-world impact of living with pulmonary fibrosis.

3. Contribute to Scleroderma Australia’s submission

We would also like to hear from people living with pulmonary fibrosis, as well as family members and carers, to help inform Scleroderma Australia’s submission.

If you would like to share your experience with us, please contact hello@sclerodermaaustralia.org.au. We may arrange a phone call or conversation to hear your story. Any information you share will be treated respectfully and used in a de-identified way to help protect your privacy.

Have Your Say

Your experience can help decision-makers better understand what it is really like to live with pulmonary fibrosis and why access to new treatment options matters.

Why not give Patient Input Buddy a go and have your say by 16 September 2026.